Guggenheim analyst Seamus Fernandez downgraded Albireo Pharma (ALBO) to Neutral from Buy after the company agreed to be acquired by Ipsen (IPSEY) for $42 per share in cash plus one contingent value right worth $10 per share payable upon the FDA approval of Bylvay in the biliary atresia indication.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALBO: